Takeda news from FiercePharma
NewsThis year's drug ads? Forget about 'em
If you ask viewers, this year's drug advertising lacks oomph. A ranking of the most-recalled DTC ads shows that consumers are having a harder time remembering them than they did last year. Some of... Read more...
AZ raises forecast; Sanofi reports 'bloodbath'
More big earnings news today, with the undisputed winner being AstraZeneca, which raised its 2008 forecast and trounced analyst expectations for the quarter. Not so lucky: Sanofi-Aventis, whose... Read more...
Moody's gives Takeda top-notch rating
Moody's Investory Services gave a thumbs up to Takeda Pharmaceuticals, with an "Aa1" issuer rating, saying the company's outlook is stable and it is likely to remain strong financially following the... Read more...
Falling dollar, falling drugmaker prices
Is the U.S. drug industry bargain-basement land right now? Analysts say that the low, low dollar means low, low prices for pharma companies. Rivals in Asia and the Eurozone could snap up drug... Read more...
| Press ReleasesPRESS RELEASE: Takeda Provides Update on Development Status of TAK-475, An Investigational Compound for Treatment of Hypercholes Takeda Provides Update on Development Status of TAK-475, An Investigational Compound for Treatment of Hypercholesterolemia OSAKA, Japan, October 29, 2007 --- Takeda Pharmaceutical Company Limited Read more >> PRESS RELEASE: Lilly and Takeda to Terminate Joint Development/Co-Marketing Agreement on Ruboxistaurin mesylate Lilly and Takeda to Terminate Joint Development/Co-Marketing Agreement on Ruboxistaurin mesylate, An Agent for the Treatment of Diabetes Microvascular Complications TOKYO--Aug. 30, 2007--Eli Lilly Read more >> |
Get more Takeda coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
